Zenas BioPharma (ZBIO) Assets (2023 - 2026)

Zenas BioPharma's Assets history runs 4 years deep, the most recent figure standing at $747.7 million for Q1 2026.

• On a quarterly basis, Assets rose 124.01% year-over-year to $747.7 million in Q1 2026; TTM through Mar 2026 was $747.7 million, a 124.01% increase from a year earlier, with the FY2025 full-year figure at $383.6 million, up 3.7% from the prior year.
• Assets rose to $747.7 million in Q1 2026 per ZBIO's latest filing, from $383.6 million in the prior quarter.
• Across five years, Assets topped out at $747.7 million in Q1 2026 and bottomed at $68.2 million in Q4 2023.
• The 4-year median for Assets is $351.9 million (2024), against an average of $365.2 million.
• Across the five-year window, Assets surged 442.63% in 2024 and decreased 20.18% in 2025, its largest moves.
• Year by year, Assets stood at $68.2 million in 2023, then jumped by 442.63% to $370.0 million in 2024, then increased by 3.7% to $383.6 million in 2025, then jumped by 94.89% to $747.7 million in 2026.
• Per Business Quant, the three latest ZBIO Assets figures stand at $747.7 million (Q1 2026), $383.6 million (Q4 2025), and $322.0 million (Q3 2025).